



Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, August 30, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of October 1, 2023.

1. Corporate Reorganization (see attached organization chart)

I. Healthcare Business Supervisory Unit:

Establishment of the Sales Promotion Department and dissolution of the Specialty Product Office

To centralize the management of data obtained through the use of digital tools and strengthen activity analysis and effect verification, the Sales Promotion Department will be established by integrating the digital strategy planning function for the domestic business, which has been carried out by the Healthcare Business Support Office under the Corporate Supervisory Unit, into the Sales Promotion Office. Furthermore, the Specialty Product Office will be dissolved by consolidating the MRs dedicated to specialty area products into the Sales Promotion Department and transferring other marketing functions to the New Product Planning Department to formulate cross-sectoral sales and marketing strategies.

II. R&D Supervisory Unit: Dissolution of the Investment Strategy Department

In addition to integrating the Investment Strategy Department into the Business Development Department, part of the function of making strategic investments outside the company will be split and transferred to the Business Administration Office under the Corporate Supervisory Unit to further enhance investment management.

2. Personnel Reassignments (Effective; October 1, 2023)

New Position	Name	Present Position
Healthcare Business Supervisory Unit		
Corporate Officer, Senior Vice President, Pharmaceutical Commercial Division	Yoshinori Yurugi	Corporate Officer, Vice President, Pharmaceutical Commercial Division
Vice President, Sales Promotion Department	Minoru Motokane	Promotion Department - Region 4
Vice President, New Business Promotion Department	Tetsuhiro Yamasaki	Sales Promotion Office
Senior Director, Corporate Social Responsibility Department, Office for Stewardship to Proper Use of Medicine	Masanori Kuroiwa	Senior Director, Sales Promotion Office

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>

